Olli Kallioniemi

List of Publications by Year
in descending order

438 papers	52,432 citations	1888 102 h-index	1496 219 g-index
460 all docs	460 docs citations	460 times ranked	50887 citing authors

#	Article	IF	Citations
1	High-throughput ex vivo drug testing identifies potential drugs and drug combinations for NRAS-positive malignant melanoma. Translational Oncology, 2022, 15, 101290.	1.7	4
2	Implementing a Functional Precision Medicine Tumor Board for Acute Myeloid Leukemia. Cancer Discovery, 2022, 12, 388-401.	7.7	73
3	Multiomics and digital monitoring during lifestyle changes reveal independent dimensions of human biology and health. Cell Systems, 2022, 13, 241-255.e7.	2.9	8
4	Stromal FAP Expression is Associated with MRI Visibility and Patient Survival in Prostate Cancer. Cancer Research Communications, 2022, 2, 172-181.	0.7	2
5	Integrative multi-omics and drug response profiling of childhood acute lymphoblastic leukemia cell lines. Nature Communications, 2022, 13, 1691.	5.8	20
6	E‐cadherin is a robust prognostic biomarker in colorectal cancer and low expression is associated with sensitivity to inhibitors of topoisomerase, aurora, and HSP90 in preclinical models. Molecular Oncology, 2022, 16, 2312-2329.	2.1	4
7	The transcriptome‐wide landscape of molecular subtype‐specific <scp>mRNA</scp> expression profiles in acute myeloid leukemia. American Journal of Hematology, 2021, 96, 580-588.	2.0	9
8	STRN-ALK rearranged pediatric malignant peritoneal mesothelioma – Functional testing of 527 cancer drugs in patient-derived cancer cells. Translational Oncology, 2021, 14, 101027.	1.7	9
9	High tumor cell platelet‐derived growth factor receptor beta expression is associated with shorter survival in malignant pleural epithelioid mesothelioma. Journal of Pathology: Clinical Research, 2021, 7, 482-494.	1.3	4
10	Bayesian multi-source regression and monocyte-associated gene expression predict BCL-2 inhibitor resistance in acute myeloid leukemia. Npj Precision Oncology, 2021, 5, 71.	2.3	12
11	The Porto European Cancer Research Summit 2021. Molecular Oncology, 2021, 15, 2507-2543.	2.1	7
12	Genetic Risk Score for Serum 25-Hydroxyvitamin D Concentration Helps to Guide Personalized Vitamin D Supplementation in Healthy Finnish Adults. Journal of Nutrition, 2021, 151, 281-292.	1.3	8
13	FLT3-ITD allelic ratio and HLF expression predict FLT3 inhibitor efficacy in adult AML. Scientific Reports, 2021, 11, 23565.	1.6	6
14	Multi-parametric single cell evaluation defines distinct drug responses in healthy hematologic cells that are retained in corresponding malignant cell types. Haematologica, 2020, 105, 1527-1538.	1.7	19
15	Glucocorticoids induce differentiation and chemoresistance in ovarian cancer by promoting ROR1-mediated stemness. Cell Death and Disease, 2020, 11, 790.	2.7	38
16	KIT pathway upregulation predicts dasatinib efficacy in acute myeloid leukemia. Leukemia, 2020, 34, 2780-2784.	3.3	6
17	Building an international consortium for tracking coronavirus health status. Nature Medicine, 2020, 26, 1161-1165.	15.2	23
18	Breeze: an integrated quality control and data analysis application for high-throughput drug screening. Bioinformatics, 2020, 36, 3602-3604.	1.8	68

#	Article	IF	Citations
19	Immune profiles in acute myeloid leukemia bone marrow associate with patient age, T-cell receptor clonality, and survival. Blood Advances, 2020, 4, 274-286.	2.5	38
20	Clonal heterogeneity influences drug responsiveness in renal cancer assessed by <i>ex vivo</i> drug testing of multiple patientâ€derived cancer cells. International Journal of Cancer, 2019, 144, 1356-1366.	2.3	29
21	Fibroblast as a critical stromal cell type determining prognosis in prostate cancer. Prostate, 2019, 79, 1505-1513.	1.2	23
22	Elevated expression of S100A8 and S100A9 correlates with resistance to the BCL-2 inhibitor venetoclax in AML. Leukemia, 2019, 33, 2548-2553.	3.3	25
23	Individual and stable autoantibody repertoires in healthy individuals. Autoimmunity, 2019, 52, 1-11.	1.2	52
24	Drug sensitivity testing on patient-derived sarcoma cells predicts patient response to treatment and identifies c-Sarc inhibitors as active drugs for translocation sarcomas. British Journal of Cancer, 2019, 120, 435-443.	2.9	24
25	Characterization of farnesyl diphosphate farnesyl transferase 1 (<i>FDFT1</i>) expression in cancer. Personalized Medicine, 2019, 16, 51-65.	0.8	17
26	Immune cell constitution in bone marrow microenvironment predicts outcome in adult ALL. Leukemia, 2019, 33, 1570-1582.	3.3	43
27	Combined epithelial marker analysis of tumour budding in stage II colorectal cancer. Journal of Pathology: Clinical Research, 2019, 5, 63-78.	1.3	20
28	Anagrelide for Gastrointestinal Stromal Tumor. Clinical Cancer Research, 2019, 25, 1676-1687.	3.2	14
29	T-cell inflamed tumor microenvironment predicts favorable prognosis in primary testicular lymphoma. Haematologica, 2019, 104, 338-346.	1.7	38
30	High-Throughput Functional Ex-Vivo Drug Testing and Multi-Omics Profiling in Patients with Acute Myeloid Leukemia. Blood, 2019, 134, 4641-4641.	0.6	1
31	Abstract 458: Precision systems medicine in acute myeloid leukemia: real-time translation of tailored therapeutic opportunities arising from ex-vivo drug sensitivity testing and molecular profiling. , 2019, , .		0
32	Abstract 2945: Clinical implementation of precision systems oncology in the treatment of ovarian cancer based on ex-vivo drug testing and molecular profiling. , 2019, , .		0
33	Spatial aspects of oncogenic signalling determine the response to combination therapy in slice explants from <i>Kras</i>â€driven lung tumours. Journal of Pathology, 2018, 245, 101-113.	2.1	19
34	Case studies investigating genetic heterogeneity between anatomically distinct bone marrow compartments in acute myeloid leukemia. Leukemia and Lymphoma, 2018, 59, 3002-3005.	0.6	0
35	Clinical relevance of integrin alpha 4 in gastrointestinal stromal tumours. Journal of Cellular and Molecular Medicine, 2018, 22, 2220-2230.	1.6	13
36	ITGB1-dependent upregulation of Caveolin-1 switches TGFÎ² signalling from tumour-suppressive to oncogenic in prostate cancer. Scientific Reports, 2018, 8, 2338.	1.6	29

#	Article	IF	Citations
37	Colorectal Cancer Consensus Molecular Subtypes Translated to Preclinical Models Uncover Potentially Targetable Cancer Cell Dependencies. Clinical Cancer Research, 2018, 24, 794-806.	3.2	177
38	Discovery of novel drug sensitivities in T-PLL by high-throughput ex vivo drug testing and mutation profiling. Leukemia, 2018, 32, 774-787.	3.3	75
39	Drug-Sensitivity Screening and Genomic Characterization of 45 HPV-Negative Head and Neck Carcinoma Cell Lines for Novel Biomarkers of Drug Efficacy. Molecular Cancer Therapeutics, 2018, 17, 2060-2071.	1.9	33
40	PD-L1+ tumor-associated macrophages and PD-1+ tumor-infiltrating lymphocytes predict survival in primary testicular lymphoma. Haematologica, 2018, 103, 1908-1914.	1.7	64
41	Association of tamoxifen resistance and lipid reprogramming in breast cancer. BMC Cancer, 2018, 18, 850.	1.1	113
42	Prognostic, predictive, and pharmacogenomic assessments of CDX2 refine stratification of colorectal cancer. Molecular Oncology, 2018, 12, 1639-1655.	2.1	40
43	Immune cell contexture in the bone marrow tumor microenvironment impacts therapy response in CML. Leukemia, 2018, 32, 1643-1656.	3.3	75
44	Comparative Analysis of Independent Ex Vivo functional Drug Screens Identifies Predictive Biomarkers of BCL-2 Inhibitor Response in AML. Blood, 2018, 132, 2763-2763.	0.6	1
45	Multi-Parametric Single Cell Profiling Defines Distinct Drug Responses in Healthy Hematological Cell Lineages That Are Retained in Corresponding Malignant Cell Types. Blood, 2018, 132, 264-264.	0.6	5
46	Predictive Response Biomarkers for BET Inhibitors in AML. Blood, 2018, 132, 2749-2749.	0.6	2
47	Abstract 5302: Phenotypic heterogeneity of patient-derived tumor cells visualized by unsupervised analysis in cell-based personalized drug testing. , 2018, , .		0
48	Abstract 3883: Gene expression predicts ex vivo drug sensitivity in acute myeloid leukemia. , 2018, , .		0
49	Abstract 5029: Precision cancer medicine based on 3D drug profiling of patient-derived cancer cell spheroid models. , 2018, , .		1
50	Abstract 2199: Establishment and high-throughput drug testing of multiple patient-derived cells from each renal cancer; intratumor heterogeneity of drug response and implications for precision medicine. , 2018, , .		0
51	Abstract 3899: Discovery and clinical implementation of individualized therapies in acute myeloid leukemia based on ex vivo drug sensitivity testing and multi-omics profiling. , 2018, , .		0
52	Quantitative Multiplex Immunohistochemistry Identifies Immunosuppression in the AML Bone Marrow and NK-Cells As Prognostic Biomarker in Intermediate-Risk Patients. Blood, 2018, 132, 2774-2774.	0.6	0
53	Comprehensive Drug Testing of Patient-derived Conditionally Reprogrammed Cells from Castration-resistant Prostate Cancer. European Urology, 2017, 71, 319-327.	0.9	74
54	Systematic drug sensitivity testing reveals synergistic growth inhibition by dasatinib or mTOR inhibitors with paclitaxel in ovarian granulosa cell tumor cells. Gynecologic Oncology, 2017, 144, 621-630.	0.6	26

#	Article	IF	Citations
55	*PLA2G7* associates with hormone receptor negativity in clinical breast cancer samples and regulates epithelial–mesenchymal transition in cultured breast cancer cells. Journal of Pathology: Clinical Research, 2017, 3, 123-138.	1.3	20
56	JAK1/2 and BCL2 inhibitors synergize to counteract bone marrow stromal cell–induced protection of AML. Blood, 2017, 130, 789-802.	0.6	90
57	Drug sensitivity and resistance testing identifies PLK1 inhibitors and gemcitabine as potent drugs for malignant peripheral nerve sheath tumors. Molecular Oncology, 2017, 11, 1156-1171.	2.1	15
58	Cell of Origin Links Histotype Spectrum to Immune Microenvironment Diversity in Non-small-Cell Lung Cancer Driven by Mutant Kras and Loss of Lkb1. Cell Reports, 2017, 18, 673-684.	2.9	47
59	Systems pathology by multiplexed immunohistochemistry and whole-slide digital image analysis. Scientific Reports, 2017, 7, 15580.	1.6	120
60	Monitoring therapy responses at the leukemic subclone level by ultra-deep amplicon resequencing in acute myeloid leukemia. Leukemia, 2017, 31, 1048-1058.	3.3	11
61	Enhanced sensitivity to glucocorticoids in cytarabine-resistant AML. Leukemia, 2017, 31, 1187-1195.	3.3	44
62	KeepEX, a simple dilution protocol for improving extracellular vesicle yields from urine. European Journal of Pharmaceutical Sciences, 2017, 98, 30-39.	1.9	59
63	HOX gene expression predicts response to BCL-2 inhibition in acute myeloid leukemia. Leukemia, 2017, 31, 301-309.	3.3	61
64	Idelalisib sensitivity and mechanisms of disease progression in relapsed TCF3-PBX1 acute lymphoblastic leukemia. Leukemia, 2017, 31, 51-57.	3.3	42
65	Crosstalk between ROR1 and BCR pathways defines novel treatment strategies in mantle cell lymphoma. Blood Advances, 2017, 1, 2257-2268.	2.5	25
66	Metabolomic Profiling of Extracellular Vesicles and Alternative Normalization Methods Reveal Enriched Metabolites and Strategies to Study Prostate Cancer-Related Changes. Theranostics, 2017, 7, 3824-3841.	4.6	167
67	The impact of RNA sequence library construction protocols on transcriptomic profiling of leukemia. BMC Genomics, 2017, 18, 629.	1.2	42
68	Drug-screening and genomic analyses of HER2-positive breast cancer cell lines reveal predictors for treatment response. Breast Cancer: Targets and Therapy, 2017, Volume 9, 185-198.	1.0	23
69	Identification and Clinical Exploration of Individualized Targeted Therapeutic Approaches in Acute Myeloid Leukemia Patients By Integrating Drug Response and Deep Molecular Profiles. Blood, 2017, 130, 854-854.	0.6	1
70	Differentiation status of primary chronic myeloid leukemia cells affects sensitivity to BCR-ABL1 inhibitors. Oncotarget, 2017, 8, 22606-22615.	0.8	13
71	Abstract 3122: Pharmacogenomic profiling to identify novel therapeutic strategies in colorectal cancer. , 2017, , .		0
72	Abstract 5732: PI3K/Akt activity regulates androgen receptor expression and predicts poor clinical outcome in non-metastatic hormone-naïve prostate cancer. , 2017, , .		1

#	Article	IF	Citations
73	Abstract 424: Landscape of somatic mutations in drug-resistant acute myeloid leukemia. , 2017, , .		0
74	Abstract 3854: Precision medicine approach: analysis of renal cancer patient-derived cells with phenomics, genomics and drug sensitivity profiling. , 2017, , .		0
75	Abstract 410: Identifying ovarian cancer specific targeted drugs using high-throughput drug sensitivity profiles of primary cancer cells. , 2017, , .		0
76	A loss-of-function genetic screening identifies novel mediators of thyroid cancer cell viability. Oncotarget, 2016, 7, 28510-28522.	0.8	15
77	Consistency in drug response profiling. Nature, 2016, 540, E5-E6.	13.7	76
78	Systematic drug screening reveals specific vulnerabilities and co-resistance patterns in endocrine-resistant breast cancer. BMC Cancer, 2016, 16, 378.	1.1	11
79	Drug response prediction by inferring pathway-response associations with kernelized Bayesian matrix factorization. Bioinformatics, 2016, 32, i455-i463.	1.8	87
80	Systematic Identification of MicroRNAs That Impact on Proliferation of Prostate Cancer Cells and Display Changed Expression in Tumor Tissue. European Urology, 2016, 69, 1120-1128.	0.9	53
81	Oncogenic Herpesvirus Utilizes Stress-Induced Cell Cycle Checkpoints for Efficient Lytic Replication. PLoS Pathogens, 2016, 12, e1005424.	2.1	30
82	Intrinsic resistance to PIM kinase inhibition in AML through p38Î±-mediated feedback activation of mTOR signaling. Oncotarget, 2016, 7, 37407-37419.	0.8	16
83	Novel drug discovery by pharmacogenomic profiling of 36 colorectal cancer cell lines.. Journal of Clinical Oncology, 2016, 34, 604-604.	0.8	0
84	Abstract 2935: Systematic drug testing and RNA-sequencing of tamoxifen resistant breast cancer cell lines. , 2016, , .		0
85	Abstract 1517: Impact of poly-A and ribo-depletion RNA-seq library construction protocols on transcriptomic analysis of samples from patients with haematological malignancies. , 2016, , .		0
86	Abstract 4679: Acquisition of cytarabine resistance leads to increased glucocorticoid sensitivity in AML. , 2016, , .		0
87	Abstract 2378: Responses of AML patients to tailored drug regimens: monitoring cancer subclones by ultra-deep resequencing. , 2016, , .		1
88	Immune Cell Profiling in CML Bone Marrow By Multiplex Immunohistochemistry. Blood, 2016, 128, 1897-1897.	0.6	0
89	High-throughput cell-based compound screen identifies pinosylvin methyl ether and tanshinone IIA as inhibitors of castration-resistant prostate cancer. Journal of Molecular Biochemistry, 2016, 5, 12-22.	0.1	7
90	Circulating tumor <scp>DNA</scp> in earlyâ€stage breast cancer: personalized biomarkers for occult metastatic disease and risk of relapse?. EMBO Molecular Medicine, 2015, 7, 994-995.	3.3	3

#	Article	IF	Citations
91	Novel drug candidates for blast phase chronic myeloid leukemia from high-throughput drug sensitivity and resistance testing. Blood Cancer Journal, 2015, 5, e309-e309.	2.8	19
92	Impact of normalization methods on high-throughput screening data with high hit rates and drug testing with dose–response data. Bioinformatics, 2015, 31, 3815-3821.	1.8	31
93	Relevance Rank Platform (RRP) for Functional Filtering of High Content Protein–Protein Interaction Data*. Molecular and Cellular Proteomics, 2015, 14, 3274-3283.	2.5	19
94	miR-183 in Prostate Cancer Cells Positively Regulates Synthesis and Serum Levels of Prostate-specific Antigen. European Urology, 2015, 68, 581-588.	0.9	35
95	Axitinib effectively inhibits BCR-ABL1(T315I) with a distinct binding conformation. Nature, 2015, 519, 102-105.	13.7	207
96	The impact of low-frequency and rare variants on lipid levels. Nature Genetics, 2015, 47, 589-597.	9.4	310
97	MicroRNA–135b regulates ERα, AR and HIF1AN and affects breast and prostate cancer cell growth. Molecular Oncology, 2015, 9, 1287-1300.	2.1	45
98	Stromal-Derived Factors Modulate Ex Vivo Drug Responses of Primary Acute Myeloid Leukemia Cells. Clinical Lymphoma, Myeloma and Leukemia, 2015, 15, S8-S9.	0.2	0
99	Androgen receptor–interacting protein <scp>HSPBAP1</scp> facilitates growth of prostate cancer cells in androgen–deficient conditions. International Journal of Cancer, 2015, 136, 2535-2545.	2.3	10
100	Abstract 3746: Novel therapeutic possibilities for chemorefractory ovarian cancer patients identified by functional ex vivo drug sensitivity testing of primary cells from ascites. , 2015, , .		1
101	Abstract POSTER-TECH-1111: High-throughput drug sensitivity and resistance testing of ovarian cancer cell lines provides useful strategy for assessing drug repositioning and therapeutic possibilities of emerging drugs. , 2015, , .		0
102	Abstract 1698: Systems pathology for characterization of cancer model systems in a multicenter IMI-PREDECT project. , 2015, , .		0
103	Abstract 676: Axitinib targets gatekeeper-mutant BCR-ABL1(T315I)-driven leukemia in a distinct and selective fashion. , 2015, , .		0
104	Abstract 207: Caveolin-1 drives oncogenic TGFβ effects in prostate cancer: in vitro mechanistic insights integrated with systems pathology visualization in primary tumor samples. , 2015, , .		0
105	BCL2-Inhibitors Target a Major Group of Newly-Diagnosed and Relapsed/Refractory Acute Myeloid Leukemia Ex Vivo. Blood, 2015, 126, 2462-2462.	0.6	0
106	JAK1/2 and BCL2 Inhibitors Synergize to Counter-Act Bone Marrow Stromal Cell-Induced Protection of AML. Blood, 2015, 126, 867-867.	0.6	0
107	Functional Screening Identifies miRNAs Influencing Apoptosis and Proliferation in Colorectal Cancer. PLoS ONE, 2014, 9, e96767.	1.1	49
108	Genetic Instability of Influenza pH1N1 Viruses. Genome Announcements, 2014, 2, .	0.8	5

#	Article	IF	Citations
109	A novel transcript, <i>VNN1â€AB</i>, as a biomarker for colorectal cancer. International Journal of Cancer, 2014, 135, 2077-2084.	2.3	18
110	Plasminogen activator urokinase expression reveals TRAIL responsiveness and supports fractional survival of cancer cells. Cell Death and Disease, 2014, 5, e1043-e1043.	2.7	25
111	Identification of structural features in chemicals associated with cancer drug response: a systematic data-driven analysis. Bioinformatics, 2014, 30, i497-i504.	1.8	33
112	Akt Inhibitor MK2206 Prevents Influenza pH1N1 Virus Infection <i>In Vitro</i>. Antimicrobial Agents and Chemotherapy, 2014, 58, 3689-3696.	1.4	38
113	Inhibition of the mitochondrial pyrimidine biosynthesis enzyme dihydroorotate dehydrogenase by doxorubicin and brequinar sensitizes cancer cells to TRAIL-induced apoptosis. Oncogene, 2014, 33, 3538-3549.	2.6	34
114	Highâ€throughput screens identify microRNAs essential for HER2 positive breast cancer cell growth. Molecular Oncology, 2014, 8, 93-104.	2.1	146
115	Break-Induced Replication Repair of Damaged Forks Induces Genomic Duplications in Human Cells. Science, 2014, 343, 88-91.	6.0	387
116	684: Helsinki Urological Biobank (HUB): A new-generation integrated biobank for facilitating precision medicine and translational research in urological cancers. European Journal of Cancer, 2014, 50, S164.	1.3	0
117	826: Primary T-prolymphocytic leukemia (T-PLL) cells are sensitive to BCL-2 and HDAC inhibitors: Results from high-throughput ex vivo drug testing. European Journal of Cancer, 2014, 50, S200.	1.3	1
118	273: Androgen receptor interacting protein HSPBAP1 facilitates growth of prostate cancer cells in androgen-deficient conditions. European Journal of Cancer, 2014, 50, S64.	1.3	0
119	Integrative and Personalized QSAR Analysis in Cancer by Kernelized Bayesian Matrix Factorization. Journal of Chemical Information and Modeling, 2014, 54, 2347-2359.	2.5	101
120	Novel activating STAT5B mutations as putative drivers of T-cell acute lymphoblastic leukemia. Leukemia, 2014, 28, 1738-1742.	3.3	90
121	A community effort to assess and improve drug sensitivity prediction algorithms. Nature Biotechnology, 2014, 32, 1202-1212.	9.4	653
122	Quantitative scoring of differential drug sensitivity for individually optimized anticancer therapies. Scientific Reports, 2014, 4, 5193.	1.6	243
123	Landscape of Mutations in Relapsed Acute Myeloid Leukemia. Blood, 2014, 124, 2367-2367.	0.6	1
124	Abstract 982: Analysis of clonal evolution of leukemia in vivo following novel targeted treatments. , 2014, , .		0
125	Abstract 5384: Systematic high-throughput drug sensitivity and resistance testing (DSRT) of ovarian cancer cell lines indicates novel therapeutic possibilities with existing and emerging drugs. , 2014, , .		0
126	Abstract 4184: Drug set enrichment analysis : A computational approach to identify functional drug sets. , 2014, , .		0

#	Article	IF	Citations
127	Discovery of Novel Drug Sensitivities in T-Prolymphocytic Leukemia (T-PLL) By High-Throughput Ex Vivo Drug Testing and Genetic Profiling. Blood, 2014, 124, 917-917.	0.6	0
128	Stroma-Derived Factors Significantly Impact the Drug Response Profiles of Patient-Derived Primary AML Cells: Implications for Drug Sensitivity Testing. Blood, 2014, 124, 3505-3505.	0.6	0
129	The Use of RNA Sequencing to Identify Disease-Specific Gene Expression Signatures and Critical Regulatory Networks Across Hematologic Malignancies. Blood, 2014, 124, 2203-2203.	0.6	3
130	Integration of Ex Vivo Drug Testing and in-Depth Molecular Profiling Reveals Oncogenic Signaling Pathways and Novel Therapeutic Strategies for Multiple Myeloma. Blood, 2014, 124, 2046-2046.	0.6	3
131	Analysis of Clonal Evolution in Chemorefractory Acute Myeloid Leukemia from Diagnosis to Relapse. Blood, 2014, 124, 1022-1022.	0.6	0
132	AML Specific Targeted Drugs Identified By Drug Sensitivity and Resistance Testing: Comparison of Ex Vivo Patient Cells with in Vitro Cell Lines. Blood, 2014, 124, 2163-2163.	0.6	1
133	A Profound Biological Difference of Chronic and Blast Phase Chronic Myeloid Leukemia in Ex Vivo Drug Responses. Blood, 2014, 124, 3139-3139.	0.6	0
134	Aneuploidy facilitates oncogenic transformation via specific genetic alterations, including Twist2 upregulation. Carcinogenesis, 2013, 34, 2000-2009.	1.3	5
135	Non-canonical Notch signaling activates IL-6/JAK/STAT signaling in breast tumor cells and is controlled by p53 and IKKα/IKKβ. Oncogene, 2013, 32, 4892-4902.	2.6	121
136	The HER2 amplicon includes several genes required for the growth and survival of HER2 positive breast cancer cells. Molecular Oncology, 2013, 7, 392-401.	2.1	80
137	Individualized Systems Medicine Strategy to Tailor Treatments for Patients with Chemorefractory Acute Myeloid Leukemia. Cancer Discovery, 2013, 3, 1416-1429.	7.7	334
138	Discovery of somatic STAT5b mutations in large granular lymphocytic leukemia. Blood, 2013, 121, 4541-4550.	0.6	252
139	Novel somatic mutations in large granular lymphocytic leukemia affecting the STAT-pathway and T-cell activation. Blood Cancer Journal, 2013, 3, e168-e168.	2.8	56
140	ARLTS1 and Prostate Cancer Risk - Analysis of Expression and Regulation. PLoS ONE, 2013, 8, e72040.	1.1	12
141	Plasticity of Blood- and Lymphatic Endothelial Cells and Marker Identification. PLoS ONE, 2013, 8, e74293.	1.1	26
142	High-Throughput 3D Screening Reveals Differences in Drug Sensitivities between Culture Models of JIMT1 Breast Cancer Cells. PLoS ONE, 2013, 8, e77232.	1.1	154
143	Novel Activating STAT5B Mutations As Drivers Of T-ALL. Blood, 2013, 122, 3863-3863.	0.6	5
144	Functional Profiling of Precursor MicroRNAs Identifies MicroRNAs Essential for Glioma Proliferation. PLoS ONE, 2013, 8, e60930.	1.1	43

#	Article	IF	Citations
145	High-throughput RNAi screening for novel modulators of vimentin expression identifies MTHFD2 as a regulator of breast cancer cell migration and invasion. Oncotarget, 2013, 4, 48-63.	0.8	95
146	Abstract 2107: Identification of alternative compounds by drug screening of HER2 positive breast cancer cell lines.. , 2013, , .		0
147	Abstract 65: Comprehensive ex vivo drug sensitivity testing combined with in depth molecular profiling of AML patients cells provides individualized treatment strategies and reveals mechanisms of drug resistance.. , 2013, , .		0
148	Abstract 5588: Functional drug sensitivity and resistance profiling of AML patient cells defines a disease-specific combination of druggable signal addictions.. , 2013, , .		0
149	Abstract 721: Multiplexed systems pathology for in-depth analysis of the tumor microenvironment: a strong correlation between pAkt and androgen receptor in the epithelial component of prostate cancer.. , 2013, , .		0
150	Abstract A34: Development of a drug sensitivity testing pipeline towards the establishment of precision medicine for ovarian cancer. , 2013, , .		0
151	Stromal Cell Supported High-Throughput Drug Testing Of Primary Leukemia Cells For Comprehensive Assessment Of Sensitivity To Novel Therapies. Blood, 2013, 122, 1668-1668.	0.6	0
152	Primary T-Prolymphocytic Leukemia (T-PLL) Cells Are Sensitive To BCL-2 and HDAC Inhibitors: Results From High-Throughput Ex Vivo Drug Testing. Blood, 2013, 122, 3828-3828.	0.6	0
153	Identification Of AML Subtype-Selective Drugs By Functional Ex Vivo Drug Sensitivity and Resistance Testing and Genomic Profiling. Blood, 2013, 122, 482-482.	0.6	0
154	High-Throughput Drug Sensitivity and Resistance Testing (DSRT) Platform Reveals Novel Candidate Drugs For Advanced Phase BCR-ABL1-Positive Leukemia. Blood, 2013, 122, 2719-2719.	0.6	0
155	Heparin-like Polysaccharides Reduce Osteolytic Bone Destruction and Tumor Growth in a Mouse Model of Breast Cancer Bone Metastasis. Molecular Cancer Research, 2012, 10, 597-604.	1.5	35
156	A functional genetic screen reveals new regulators of Î²1-integrin activity. Journal of Cell Science, 2012, 125, 649-661.	1.2	38
157	c-Jun N-Terminal Kinase Phosphorylation of MARCKSL1 Determines Actin Stability and Migration in Neurons and in Cancer Cells. Molecular and Cellular Biology, 2012, 32, 3513-3526.	1.1	68
158	HES6 gene is selectively overexpressed in glioma and represents an important transcriptional regulator of glioma proliferation. Oncogene, 2012, 31, 1299-1310.	2.6	33
159	Somatic *STAT3* Mutations in Large Granular Lymphocytic Leukemia. New England Journal of Medicine, 2012, 366, 1905-1913.	13.9	681
160	Lysophosphatidic acid and sphingosine-1-phosphate promote morphogenesis and block invasion of prostate cancer cells in three-dimensional organotypic models. Oncogene, 2012, 31, 2075-2089.	2.6	44
161	Cytokinesis failure due to derailed integrin traffic induces aneuploidy and oncogenic transformation in vitro and in vivo. Oncogene, 2012, 31, 3597-3606.	2.6	48
162	Interaction with ErbB4 Promotes Hypoxia-inducible Factor-1Î± Signaling. Journal of Biological Chemistry, 2012, 287, 9659-9671.	1.6	40

#	ARTICLE	IF	CITATIONS
163	Salinomycin inhibits prostate cancer growth and migration via induction of oxidative stress. British Journal of Cancer, 2012, 106, 99-106.	2.9	141
164	An integrated genomic approach identifies ARID1A as a candidate tumor-suppressor gene in breast cancer. Oncogene, 2012, 31, 2090-2100.	2.6	111
165	338 The HER2 Amplicon Includes Several Genes Required for the Growth and Survival of HER2 Positive Breast Cancer Cells. European Journal of Cancer, 2012, 48, S82-S83.	1.3	0
166	589 Precursor MicroRNA Functional Profiling Identifies MicroRNAs Essential for Glioblastoma Proliferation. European Journal of Cancer, 2012, 48, S140.	1.3	0
167	681 Aneuploidy Facilitates Oncogenic Transformation Via Specific Genetic Alterations. European Journal of Cancer, 2012, 48, S161.	1.3	0
168	825 Exome Sequencing of T-LGL Leukemia Patient Revealed ANGPT2 as a Possible Mutational Target. European Journal of Cancer, 2012, 48, S198.	1.3	0
169	The gene expression landscape of breast cancer is shaped by tumor protein p53 status and epithelial-mesenchymal transition. Breast Cancer Research, 2012, 14, R113.	2.2	49
170	MiR-9, -31, and -182 Deregulation Promote Proliferation and Tumor Cell Survival in Colon Cancer. Neoplasia, 2012, 14, 868-IN21.	2.3	124
171	Systematic knockdown of epigenetic enzymes identifies a novel histone demethylase PHF8 overexpressed in prostate cancer with an impact on cell proliferation, migration and invasion. Oncogene, 2012, 31, 3444-3456.	2.6	112
172	Comprehensive data-driven analysis of the impact of chemoinformatic structure on the genome-wide biological response profiles of cancer cells to 1159 drugs. BMC Bioinformatics, 2012, 13, 112.	1.2	16
173	461 Identification of Personalized Therapeutic Strategies and Associated Biomarkers in Adult Acute Myeloid Leukemia Using a Functional Drug Sensitivity and Resistance Testing Platform. European Journal of Cancer, 2012, 48, 142-143.	1.3	0
174	Integration of Metabolomics and Expression of Glycerol-3-phosphate Acyltransferase (GPAM) in Breast Cancer—Link to Patient Survival, Hormone Receptor Status, and Metabolic Profiling. Journal of Proteome Research, 2012, 11, 850-860.	1.8	68
175	Identification of MicroRNAs Inhibiting TGF-Î²-Induced IL-11 Production in Bone Metastatic Breast Cancer Cells. PLoS ONE, 2012, 7, e37361.	1.1	72
176	High-Throughput Transcriptomic and RNAi Analysis Identifies AIM1, ERGIC1, TMED3 and TPX2 as Potential Drug Targets in Prostate Cancer. PLoS ONE, 2012, 7, e39801.	1.1	54
177	15â€Hydroxyprostaglandin dehydrogenase associates with poor prognosis in breast cancer, induces epithelialâ€"mesenchymal transition, and promotes cell migration in cultured breast cancer cells. Journal of Pathology, 2012, 226, 674-686.	2.1	32
178	Integrative genomic, transcriptomic, and RNAi analysis indicates a potential oncogenic role for FAM110B in castrationâ€resistant prostate cancer. Prostate, 2012, 72, 789-802.	1.2	30
179	Abstract 2984: A comprehensive bioinformatic analysis of the representativity of 460 cancer cell lines as model systems for 88 different clinical cancer types. , 2012, , .		1
180	Abstract 3175: Genomic and transcriptomic data integration in chronic myelomonocytic leukemia reveals a novel fusion gene involving onco-miR-125b-2. , 2012, , .		3

#	ARTICLE	IF	CITATIONS
181	Abstract 4580: Personalized treatment selection for therapy-resistant AML by integrating ex-vivo drug sensitivity and resistance testing (DSRT) as well as serial genomic, transcriptomic and phosphoproteomic profiling. , 2012, , .		1
182	Abstract 5067: Exome sequencing reveals both DNA sequence and copy number changes in AML: Potential driver changes and mechanisms of drug resistance revealed from serial samples from the same patients. , 2012, , .		1
183	Discovery of STAT5b Mutations and Small Subclones of STAT3 Mutations in Large Granular Lymphocytic (LGL) Leukemia. Blood, 2012, 120, 871-871.	0.6	2
184	Reanalysis of RNA-Sequencing Data Reveals Several Additional Fusion Genes with Multiple Isoforms. PLoS ONE, 2012, 7, e48745.	1.1	72
185	Systemic Analysis of Gene Expression Profiles Identifies ErbB3 as a Potential Drug Target in Pediatric Alveolar Rhabdomyosarcoma. PLoS ONE, 2012, 7, e50819.	1.1	9
186	Chemical Biology Drug Sensitivity Screen Identifies Sunitinib as Synergistic Agent with Disulfiram in Prostate Cancer Cells. PLoS ONE, 2012, 7, e51470.	1.1	24
187	Abstract 895: Quantitative drug sensitivity and resistance testing (DSRT) of primary ex vivo AML blasts highlights mTOR and MEK as potential key molecular driver signals of therapeutic significance. , 2012, , .		0
188	Abstract 3188: Development of a cancer pharmacopeia-wide ex-vivo drug sensitivity and resistance testing (DSRT) platform for AML: Towards individually optimized therapy and improved understanding of drug resistance patterns. , 2012, , .		0
189	Abstract 334: Identification of novel regulatory genes controlling epithelial to mesenchymal transition in cultured breast cancer cells. , 2012, , .		0
190	High-Throughput Ex Vivo Drug Sensitivity and Resistance Testing (DSRT) Integrated with Deep Genomic and Molecular Profiling Reveal New Therapy Options with Targeted Drugs in Subgroups of Relapsed Chemorefractory AML. Blood, 2012, 120, 288-288.	0.6	1
191	Somatic PTPRT and ANGPT2 Mutations in Large Granulocyte Leukemia. Blood, 2012, 120, 1302-1302.	0.6	0
192	SHARPIN is an endogenous inhibitor of Î²1-integrin activation. Nature Cell Biology, 2011, 13, 1315-1324.	4.6	184
193	Identification of fusion genes in breast cancer by paired-end RNA-sequencing. Genome Biology, 2011, 12, R6.	13.9	301
194	Classification of unknown primary tumors with a data-driven method based on a large microarray reference database. Genome Medicine, 2011, 3, 63.	3.6	12
195	Arachidonic Acid Pathway Members PLA2G7, HPGD, EPHX2, and CYP4F8 Identified as Putative Novel Therapeutic Targets in Prostate Cancer. American Journal of Pathology, 2011, 178, 525-536.	1.9	102
196	Emerging molecular biomarkersâ€"blood-based strategies to detect and monitor cancer. Nature Reviews Clinical Oncology, 2011, 8, 142-150.	12.5	277
197	Contribution of ARLTS1 Cys148Arg (T442C) Variant with Prostate Cancer Risk and ARLTS1 Function in Prostate Cancer Cells. PLoS ONE, 2011, 6, e26595.	1.1	8
198	SATB2 in Combination With Cytokeratin 20 Identifies Over 95% of all Colorectal Carcinomas. American Journal of Surgical Pathology, 2011, 35, 937-948.	2.1	209

#	Article	IF	Citations
199	MicroRNA in Prostate, Bladder, and Kidney Cancer: A Systematic Review. European Urology, 2011, 59, 671-681.	0.9	401
200	Enhanced serine production by bone metastatic breast cancer cells stimulates osteoclastogenesis. Breast Cancer Research and Treatment, 2011, 125, 421-430.	1.1	222
201	Alignment of gene expression profiles from test samples against a reference database: New method for context-specific interpretation of microarray data. BioData Mining, 2011, 4, 5.	2.2	5
202	A cell spot microarray method for production of high density siRNA transfection microarrays. BMC Genomics, 2011, 12, 162.	1.2	50
203	Androgen regulation of micro€RNAs in prostate cancer. Prostate, 2011, 71, 604-614.	1.2	144
204	The miR€15a€miR€16€1 locus is homozygously deleted in a subset of prostate cancers. Genes Chromosomes and Cancer, 2011, 50, 499-509.	1.5	42
205	Identification of miR-193b Targets in Breast Cancer Cells and Systems Biological Analysis of Their Functional Impact. Molecular and Cellular Proteomics, 2011, 10, M110.005322.	2.5	60
206	KRAS Oncogene Rearrangements and Gene Fusions: Unexpected Rare Encounters in Late-Stage Prostate Cancers: Table 1.. Cancer Discovery, 2011, 1, 12-13.	7.7	3
207	Novel Theranostic Opportunities Offered by Characterization of Altered Membrane Lipid Metabolism in Breast Cancer Progression. Cancer Research, 2011, 71, 3236-3245.	0.4	444
208	Systematic Analysis of MicroRNAs Targeting the Androgen Receptor in Prostate Cancer Cells. Cancer Research, 2011, 71, 1956-1967.	0.4	244
209	Dual role of FoxA1 in androgen receptor binding to chromatin, androgen signalling and prostate cancer. EMBO Journal, 2011, 30, 3962-3976.	3.5	318
210	On the organization of bioinformatics core services in biology-based research institutes. Bioinformatics, 2011, 27, 1345-1345.	1.8	9
211	Abstract 3977: Systematic analysis of microRNAs targeting the androgen receptor in prostate cancer cells. , 2011, , .		3
212	Abstract 52: A new method to interpret gene expression microarray data for individual tumors by profile alignment against a reference dataset of 10,000 samples. , 2011, , .		1
213	miRNA-mRNA Integrated Analysis Reveals Roles for miRNAs in Primary Breast Tumors. PLoS ONE, 2011, 6, e16915.	1.1	278
214	GTI: A Novel Algorithm for Identifying Outlier Gene Expression Profiles from Integrated Microarray Datasets. PLoS ONE, 2011, 6, e17259.	1.1	29
215	Phospholipase PLA2G7, associated with aggressive prostate cancer, promotes prostate cancer cell migration and invasion and is inhibited by statins. Oncotarget, 2011, 2, 1176-1190.	0.8	77
216	Abstract 3800: HES6 gene is a strong glioma biomarker and a key transcriptional regulator needed for cancer cell growth. , 2011, , .		0

#	Article	IF	Citations
217	Abstract 2597: PLA2G7 associates with aggressive prostate cancer in vivo and regulates prostate cancer cell migration and adhesion in vitro. , 2011, , .		0
218	Abstract 4836: In vitro drug sensitivity testing along with full genome and transcriptome sequencing and phosphoproteomics: Comprehensive â€œnext-generationâ€•molecular oncology portrait of a sarcoma for facilitating treatment decisions. , 2011, , .		0
219	Abstract 4850: Paired-end RNA-sequencing based identification of 24 novel fusion genes in breast cancer. , 2011, , .		0
220	Abstract 845: Heparin-like polysaccharides reduce osteolytic bone destruction and tumor growth in a mouse model of breast cancer bone metastasis. , 2011, , .		1
221	Abstract 4023: ARID1A is a candidate tumor suppressor gene in breast cancer. , 2011, , .		0
222	Development of a Cancer Pharmacopeia-Wide Ex-Vivo Drug Sensitivity and Resistance Testing (DSRT) Platform: Identification of MEK and mTOR As Patient-Specific Molecular Drivers of Adult AML and Potent Therapeutic Combinations with Dasatinib. Blood, 2011, 118, 2487-2487.	0.6	0
223	Recurrent Missense Mutations in the STAT3 Gene in LGL Leukemia Provide Insights to Pathogenetic Mechanisms and Suggest Potential Diagnostic and Therapeutic Applications. Blood, 2011, 118, 936-936.	0.6	6
224	Interactions between Notch- and hypoxia-induced transcriptomes in embryonic stem cells. Experimental Cell Research, 2010, 316, 1610-1624.	1.2	30
225	Use of cancerâ€specific genomic rearrangements to quantify disease burden in plasma from patients with solid tumors. Genes Chromosomes and Cancer, 2010, 49, 1062-1069.	1.5	172
226	International network of cancer genome projects. Nature, 2010, 464, 993-998.	13.7	2,114
227	A Comprehensive Panel of Three-Dimensional Models for Studies of Prostate Cancer Growth, Invasion and Drug Responses. PLoS ONE, 2010, 5, e10431.	1.1	299
228	Analysis of Kinase Gene Expression Patterns across 5681 Human Tissue Samples Reveals Functional Genomic Taxonomy of the Kinome. PLoS ONE, 2010, 5, e15068.	1.1	44
229	Monensin Is a Potent Inducer of Oxidative Stress and Inhibitor of Androgen Signaling Leading to Apoptosis in Prostate Cancer Cells. Molecular Cancer Therapeutics, 2010, 9, 3175-3185.	1.9	80
230	Fibroblast Growth Factor Receptor 4 Regulates Tumor Invasion by Coupling Fibroblast Growth Factor Signaling to Extracellular Matrix Degradation. Cancer Research, 2010, 70, 7851-7861.	0.4	49
231	Cancer Genomes. Clinical Chemistry, 2010, 56, 1660-1664.	1.5	5
232	*FZD4* as a Mediator of *ERG* Oncogeneâ€"Induced WNT Signaling and Epithelial-to-Mesenchymal Transition in Human Prostate Cancer Cells. Cancer Research, 2010, 70, 6735-6745.	0.4	229
233	Epigenetics of prostate cancer and the prospect of identification of novel drug targets by RNAi screening of epigenetic enzymes. Epigenomics, 2010, 2, 683-689.	1.0	6
234	558 Systematic functional analysis of microRNAs by transfection of 1129 miRNAs into prostate cancer cells. European Journal of Cancer, Supplement, 2010, 8, 177.	2.2	0

#	ARTICLE	IF	CITATIONS
235	Integrative Functional Genomics Analysis of Sustained Polyploidy Phenotypes in Breast Cancer Cells Identifies an Oncogenic Profile for GINS2. Neoplasia, 2010, 12, 877-IN14.	2.3	44
236	Abstract 1953: Functional identification of microRNA targets by integrated proteomics and microarray profiling: miR-193b in breast cancer. , 2010, , .		0
237	Abstract 2072: Systematic functional analysis of microRNAs by transfection of 1129 miRNAs into prostate cancer cells. , 2010, , .		0
238	Mammary-Derived Growth Inhibitor Alters Traffic of EGFR and Induces a Novel Form of Cetuximab Resistance. Clinical Cancer Research, 2009, 15, 6570-6581.	3.2	33
239	Dietary flavonoid fisetin induces a forced exit from mitosis by targeting the mitotic spindle checkpoint. Carcinogenesis, 2009, 30, 1032-1040.	1.3	49
240	High-Throughput Cell-Based Screening of 4910 Known Drugs and Drug-like Small Molecules Identifies Disulfiram as an Inhibitor of Prostate Cancer Cell Growth. Clinical Cancer Research, 2009, 15, 6070-6078.	3.2	185
241	CIP2A Is Associated with Human Breast Cancer Aggressivity. Clinical Cancer Research, 2009, 15, 5092-5100.	3.2	205
242	Comparison of Affymetrix data normalization methods using 6,926 experiments across five array generations. BMC Bioinformatics, 2009, 10, S24.	1.2	35
243	Comparison of structure fingerprint and molecular interaction field based methods in explaining biological similarity of small molecules in cell-based screens. Journal of Computer-Aided Molecular Design, 2009, 23, 227-239.	1.3	9
244	Data integration from two microarray platforms identifies bi-allelic genetic inactivation of RIC8Ain a breast cancer cell line. BMC Medical Genomics, 2009, 2, 26.	0.7	8
245	Protein lysate microarray analysis to identify microRNAs regulating estrogen receptor signaling in breast cancer cell lines. Oncogene, 2009, 28, 3926-3936.	2.6	205
246	Critical Comparison of Virtual Screening Methods against the MUV Data Set. Journal of Chemical Information and Modeling, 2009, 49, 2168-2178.	2.5	42
247	The transcription factor Sox11 is a prognostic factor for improved recurrence-free survival in epithelial ovarian cancer. European Journal of Cancer, 2009, 45, 1510-1517.	1.3	79
248	A Decade of Cancer Gene Profiling: From Molecular Portraits to Molecular Function. Methods in Molecular Biology, 2009, 576, 61-87.	0.4	13
249	Role of ErbB4 in Breast Cancer. Journal of Mammary Gland Biology and Neoplasia, 2008, 13, 259-268.	1.0	121
250	Functional evidence implicating S100P in prostate cancer progression. International Journal of Cancer, 2008, 123, 330-339.	2.3	61
251	Defining the molecular action of HDAC inhibitors and synergism with androgen deprivation in ERGâ€positive prostate cancer. International Journal of Cancer, 2008, 123, 2774-2781.	2.3	60
252	The BOADICEA model of genetic susceptibility to breast and ovarian cancers: updates and extensions. British Journal of Cancer, 2008, 98, 1457-1466.	2.9	461

#	Article	IF	Citations
253	Systematic bioinformatic analysis of expression levels of 17,330 human genes across 9,783 samples from 175 types of healthy and pathological tissues. Genome Biology, 2008, 9, R139.	13.9	234
254	Application of Active and Kinase-Deficient Kinome Collection for Identification of Kinases Regulating Hedgehog Signaling. Cell, 2008, 133, 537-548.	13.5	171
255	P26. MicroRNA expression profiling and functional screening in bone metastatic breast cancer cells. Cancer Treatment Reviews, 2008, 34, 22.	3.4	2
256	Integrin Trafficking Regulated by Rab21 Is Necessary for Cytokinesis. Developmental Cell, 2008, 15, 371-385.	3.1	177
257	Cancer genome analysis: a landscape seen from many angles. Drug Discovery Today Disease Mechanisms, 2007, 4, 269-276.	0.8	0
258	Claudin-1 overexpression in melanoma is regulated by PKC and contributes to melanoma cell motility. Oncogene, 2007, 26, 3846-3856.	2.6	155
259	ProteomeBinders: planning a European resource of affinity reagents for analysis of the human proteome. Nature Methods, 2007, 4, 13-17.	9.0	231
260	A new look towards BAC-based array CGH through a comprehensive comparison with oligo-based array CGH. BMC Genomics, 2007, 8, 84.	1.2	39
261	Evaluation of the role of Finnish ataxia-telangiectasia mutations in hereditary predisposition to breast cancer. Carcinogenesis, 2006, 28, 1040-1045.	1.3	21
262	TMPRSS2 Fusions with Oncogenic ETS Factors in Prostate Cancer Involve Unbalanced Genomic Rearrangements and Are Associated with HDAC1 and Epigenetic Reprogramming. Cancer Research, 2006, 66, 10242-10246.	0.4	209
263	The weibull distribution based normalization method for affymetrix gene expression microarray data. , 2006, , .		0
264	BARD1 variants Cys557Ser and Val507Met in breast cancer predisposition. European Journal of Human Genetics, 2006, 14, 167-172.	1.4	41
265	Identification of target genes in laryngeal squamous cell carcinoma by high-resolution copy number and gene expression microarray analyses. Oncogene, 2006, 25, 6997-7008.	2.6	88
266	Integrated breast cancer genomics. Cancer Cell, 2006, 10, 453-454.	7.7	5
267	Human Protein Atlas charts a diverse terrain. Trends in Biotechnology, 2006, 24, 195-197.	4.9	25
268	Profiling Genetic Variation along the Androgen Biosynthesis and Metabolism Pathways Implicates Several Single Nucleotide Polymorphisms and Their Combinations as Prostate Cancer Risk Factors. Cancer Research, 2006, 66, 743-747.	0.4	54
269	Novel Genomic Aberrations in Testicular Germ Cell Tumors by Array-CGH, and Associated Gene Expression Changes. Analytical Cellular Pathology, 2006, 28, 315-326.	0.7	54
270	Application of Microarray Technologies for Translational Genomics. Biological and Medical Physics Series, 2005, , 361-374.	0.3	0

#	ARTICLE	IF	CITATIONS
271	Functional genomics and transcriptomics of prostate cancer: promises and limitations. BJU International, 2005, 96, 10-15.	1.3	7
272	Correlation of CHEK2 protein expression and c.1100delC mutation status with tumor characteristics among unselected breast cancer patients. International Journal of Cancer, 2005, 113, 575-580.	2.3	97
273	Hereditary prostate cancer in Finland: fine-mapping validates 3p26 as a major predisposition locus. Human Genetics, 2005, 116, 43-50.	1.8	25
274	A major locus for hereditary prostate cancer in Finland: localization by linkage disequilibrium of a haplotype in the HPCX region. Human Genetics, 2005, 117, 307-316.	1.8	30
275	EphB2 Expression across 138 Human Tumor Types in a Tissue Microarray: High Levels of Expression in Gastrointestinal Cancers. Clinical Cancer Research, 2005, 11, 6450-6458.	3.2	81
276	Breast and ovarian cancer risks to carriers of the BRCA1 5382insC and 185delAG and BRCA2 6174delT mutations: a combined analysis of 22 population based studies. Journal of Medical Genetics, 2005, 42, 602-603.	1.5	121
277	Differentiation of Human Embryonal Carcinomas In vitro and In vivo Reveals Expression Profiles Relevant to Normal Development. Cancer Research, 2005, 65, 5588-5598.	0.4	194
278	Dissection of molecular pathways of cancer by high-throughput biochip technologies and RNA interference. Breast Cancer Research, 2005, 7, 1.	2.2	1
279	NMD Microarray Analysis for Rapid Genome-Wide Screen of Mutated Genes in Cancer. Analytical Cellular Pathology, 2005, 27, 169-173.	0.7	7
280	Prognostic Impact of ANX7-GTPase in Metastatic and HER2-Negative Breast Cancer Patients. Clinical Cancer Research, 2004, 10, 2344-2350.	3.2	42
281	Nonsense-mediated decay microarray analysis identifies mutations of EPHB2 in human prostate cancer. Nature Genetics, 2004, 36, 979-983.	9.4	180
282	Genome-wide scanning for linkage in Finnish breast cancer families. European Journal of Human Genetics, 2004, 12, 98-104.	1.4	27
283	Claes Lundsteen—in Memoriam. European Journal of Human Genetics, 2004, 12, 603-603.	1.4	0
284	Generation and analysis of melanoma SAGE libraries: SAGE advice on the melanoma transcriptome. Oncogene, 2004, 23, 2264-2274.	2.6	71
285	Medicine: Profile of a tumour. Nature, 2004, 428, 379-382.	13.7	20
286	CHEK2 1100delC is not a risk factor for male breast cancer population. International Journal of Cancer, 2004, 108, 475-476.	2.3	55
287	CHEK2 variant I157T may be associated with increased breast cancer risk. International Journal of Cancer, 2004, 111, 543-547.	2.3	134
288	A strategy for identifying putative causes of gene expression variation in human cancers. Journal of the Franklin Institute, 2004, 341, 77-88.	1.9	21

#	Article	IF	Citations
289	High-Resolution Analysis of Gene Copy Number Alterations in Human Prostate Cancer Using CGH on cDNA Microarrays: Impact of Copy Number on Gene Expression. Neoplasia, 2004, 6, 240-247.	2.3	110
290	BRCA2 Mutations in 154 Finnish Male Breast Cancer Patients. Neoplasia, 2004, 6, 541-545.	2.3	33
291	Are data from different gene expression microarray platforms comparable?. Genomics, 2004, 83, 1164-1168.	1.3	179
292	High-throughput RNAi screening identifies sensitizing targets to improve doxorubicin chemotherapy. Journal of Clinical Oncology, 2004, 22, 9543-9543.	0.8	0
293	Title is missing!. Machine Learning, 2003, 52, 45-66.	3.4	44
294	Androgen Receptor Gene Alterations in Finnish Male Breast Cancer. Breast Cancer Research and Treatment, 2003, 77, 167-170.	1.1	34
295	Genome-wide scan for linkage in finnish hereditary prostate cancer (HPC) families identifies novel susceptibility loci at 11q14 and 3p25-26. Prostate, 2003, 57, 280-289.	1.2	47
296	Loss of the tight junction protein claudin-7 correlates with histological grade in both ductal carcinoma in situ and invasive ductal carcinoma of the breast. Oncogene, 2003, 22, 2021-2033.	2.6	415
297	High frequency of BRAF mutations in nevi. Nature Genetics, 2003, 33, 19-20.	9.4	1,547
298	RNAi Microarray Analysis in Cultured Mammalian Cells. Genome Research, 2003, 13, 2341-2347.	2.4	173
299	Average Risks of Breast and Ovarian Cancer Associated with BRCA1 or BRCA2 Mutations Detected in Case Series Unselected for Family History: A Combined Analysis of 22 Studies. American Journal of Human Genetics, 2003, 72, 1117-1130.	2.6	3,105
300	Candidate Genes for Testicular Cancer Evaluated by In Situ Protein Expression Analyses on Tissue Microarrays. Neoplasia, 2003, 5, 397-404.	2.3	46
301	BRCA1 and BRCA2 mutations have no major role in predisposition to prostate cancer in Finland. Journal of Medical Genetics, 2003, 40, 98e-98.	1.5	22
302	Topoisomerase-IIα Is Upregulated in Malignant Peripheral Nerve Sheath Tumors and Associated With Clinical Outcome. Journal of Clinical Oncology, 2003, 21, 4586-4591.	0.8	74
303	New Paraoxonase 1 Polymorphism I102V and the Risk of Prostate Cancer in Finnish Men. Journal of the National Cancer Institute, 2003, 95, 812-818.	3.0	62
304	A novel strategy for microarray quality control using Bayesian networks. Bioinformatics, 2003, 19, 2031-2038.	1.8	48
305	Morphological spot counting from stacked images for automated analysis of gene copy numbers by fluorescence in situ hybridization. Journal of Biomedical Optics, 2002, 7, 109.	1.4	20
306	Expression of Cytokeratins 17 and 5 Identifies a Group of Breast Carcinomas with Poor Clinical Outcome. American Journal of Pathology, 2002, 161, 1991-1996.	1.9	494

#	Article	IF	Citations
307	Expression of Bcl-2 Family Member Bid in Normal and Malignant Tissues. Neoplasia, 2002, 4, 129-140.	2.3	82
308	Germline Alterations of the RNASEL Gene, a Candidate HPC1 Gene at 1q25, in Patients and Families with Prostate Cancer. American Journal of Human Genetics, 2002, 70, 1299-1304.	2.6	202
309	A CHEK2 Genetic Variant Contributing to a Substantial Fraction of Familial Breast Cancer. American Journal of Human Genetics, 2002, 71, 432-438.	2.6	402
310	Simulation Toolbox for 3D-FISH Spot-Counting Algorithms. Real Time Imaging, 2002, 8, 203-212.	1.6	15
311	Cloning ofBCAS3(17q23) andBCAS4(20q13) genes that undergo amplification, overexpression, and fusion in breast cancerâ€. Genes Chromosomes and Cancer, 2002, 35, 311-317.	1.5	100
312	A genomic map of a 6-Mb region at 13q21-q22 implicated in cancer development: identification and characterization of candidate genes. Human Genetics, 2002, 110, 111-121.	1.8	66
313	Androgen receptor CAG polymorphism and prostate cancer risk. Human Genetics, 2002, 111, 166-171.	1.8	61
314	Clinical and functional target validation using tissue and cell microarrays. Current Opinion in Chemical Biology, 2002, 6, 97-101.	2.8	41
315	Germline mutations in the ribonuclease L gene in families showing linkage with HPC1. Nature Genetics, 2002, 30, 181-184.	9.4	470
316	Tissue Microarrays for Rapid Linking of Molecular Changes to Clinical Endpoints. American Journal of Pathology, 2001, 159, 2249-2256.	1.9	521
317	Gene-Expression Profiles in Hereditary Breast Cancer. New England Journal of Medicine, 2001, 344, 539-548.	13.9	1,669
318	Biochip technologies in cancer research. Annals of Medicine, 2001, 33, 142-147.	1.5	79
319	Tissue microarray technology for high-throughput molecular profiling of cancer. Human Molecular Genetics, 2001, 10, 657-662.	1.4	479
320	CGH, cDNA and Tissue Microarray Analyses Implicate *FGFR2* Amplification in a Small Subset of Breast Tumors. Analytical Cellular Pathology, 2001, 22, 229-234.	2.1	60
321	ANX7 as a Bio-Marker in Prostate and Breast Cancer Progression. Disease Markers, 2001, 17, 115-120.	0.6	32
322	Tissue Microarrays: What Will They Bring to Molecular and Anatomic Pathology?. Advances in Anatomic Pathology, 2001, 8, 14-20.	2.4	133
323	Genetic changes in familial prostate cancer by comparative genomic hybridization. Prostate, 2001, 46, 233-239.	1.2	29
324	Tissue microarrays (TMAs) for high-throughput molecular pathology research. International Journal of Cancer, 2001, 94, 1-5.	2.3	220

#	Article	IF	Citations
325	From chromosomal alterations to target genes for therapy: integrating cytogenetic and functional genomic views of the breast cancer genome. Seminars in Cancer Biology, 2001, 11, 395-401.	4.3	22
326	Relatives of prostate cancer patients have an increased risk of prostate and stomach cancers: a population-based, cancer registry study in Finland. Cancer Causes and Control, 2001, 12, 223-230.	0.8	42
327	Germline TP53 alterations in Finnish breast cancer families are rare and occur at conserved mutation-prone sites. British Journal of Cancer, 2001, 84, 116-119.	2.9	38
328	Haplotype analysis in Icelandic and Finnish BRCA2 999del5 breast cancer families. European Journal of Human Genetics, 2001, 9, 773-779.	1.4	23
329	Amplification and overexpression of PRUNE in human sarcomas and breast carcinomas–a possible mechanism for altering the nm23-H1 activity. Oncogene, 2001, 20, 6881-6890.	2.6	52
330	Failure of hormone therapy in prostate cancer involves systematic restoration of androgen responsive genes and activation of rapamycin sensitive signaling. Oncogene, 2001, 20, 6718-6723.	2.6	122
331	RESPONSE: Re: Population-Based Study of BRCA1 and BRCA2 Mutations in 1035 Unselected Finnish Breast Cancer Patients. Journal of the National Cancer Institute, 2001, 93, 153-154.	3.0	1
332	A missense substitution A49T in the steroid 5-alpha-reductase gene (SRD5A2) is not associated with prostate cancer in Finland. British Journal of Cancer, 2001, 84, 1344-1347.	2.9	47
333	ANX7, a candidate tumor suppressor gene for prostate cancer. Proceedings of the National Academy of Sciences of the United States of America, 2001, 98, 4575-4580.	3.3	128
334	Nationwide cancer family ascertainment using Finnish cancer registry data on family names and places of birth for 35,761 prostate cancer patients. International Journal of Cancer, 2000, 88, 307-312.	2.3	6
335	Multiple founder effects and geographical clustering of BRCA1 and BRCA2 families in Finland. European Journal of Human Genetics, 2000, 8, 757-763.	1.4	75
336	Novel findings in gene expression detected in human osteosarcoma by cDNA microarray. Cancer Genetics and Cytogenetics, 2000, 123, 128-132.	1.0	60
337	Somatic deletions in hereditary breast cancers implicate 13q21 as a putative novel breast cancer susceptibility locus. Proceedings of the National Academy of Sciences of the United States of America, 2000, 97, 9603-9608.	3.3	153
338	Distance-Based Reconstruction of Tree Models for Oncogenesis. Journal of Computational Biology, 2000, 7, 789-803.	0.8	96
339	Population-Based Study of BRCA1 and BRCA2 Mutations in 1035 Unselected Finnish Breast Cancer Patients. Journal of the National Cancer Institute, 2000, 92, 1529-1531.	3.0	159
340	Detecting Activation of Ribosomal Protein S6 Kinase by Complementary DNA and Tissue Microarray Analysis. Journal of the National Cancer Institute, 2000, 92, 1252-1259.	3.0	251
341	High-Throughput Tissue Microarray Analysis of Cyclin E Gene Amplification and Overexpression in Urinary Bladder Cancer. American Journal of Pathology, 2000, 157, 787-794.	1.9	232
342	ANDROGEN RECEPTOR GENE AMPLIFICATION AT PRIMARY PROGRESSION PREDICTS RESPONSE TO COMBINED ANDROGEN BLOCKADE AS SECOND LINE THERAPY FOR ADVANCED PROSTATE CANCER. Journal of Urology, 2000, 164, 1992-1995.	0.2	134

#	Article	IF	Citations
343	Genotyping of Adrenocortical Tumors: Very Frequent Deletions of the MEN1 Locus in 11q13 and of a 1-Centimorgan Region in 2p161. Journal of Clinical Endocrinology and Metabolism, 1999, 84, 730-735.	1.8	97
344	A Nuclear Factor, ASC-2, as a Cancer-amplified Transcriptional Coactivator Essential for Ligand-dependent Transactivation by Nuclear Receptors in Vivo. Journal of Biological Chemistry, 1999, 274, 34283-34293.	1.6	190
345	Hormone Therapy Failure in Human Prostate Cancer: Analysis by Complementary DNA and Tissue Microarrays. Journal of the National Cancer Institute, 1999, 91, 1758-1764.	3.0	325
346	Molecular cytogenetic analysis of 11 new breast cancer cell lines. British Journal of Cancer, 1999, 81, 1328-1334.	2.9	186
347	Inferring Tree Models for Oncogenesis from Comparative Genome Hybridization Data. Journal of Computational Biology, 1999, 6, 37-51.	0.8	202
348	Somatic genetic alterations inBRCA2-associated and sporadic male breast cancer. , 1999, 24, 56-61.		50
349	High-Throughput Tissue Microarray Analysis to Evaluate Genes Uncovered by cDNA Microarray Screening in Renal Cell Carcinoma. American Journal of Pathology, 1999, 154, 981-986.	1.9	376
350	Genotyping of Adrenocortical Tumors: Very Frequent Deletions of the MEN1 Locus in 11q13 and of a 1-Centimorgan Region in 2p16. Journal of Clinical Endocrinology and Metabolism, 1999, 84, 730-735.	1.8	76
351	Evidence for a prostate cancer susceptibility locus on the X chromosome.. Nature Genetics, 1998, 20, 175-179.	9.4	641
352	Tissue microarrays for high-throughput molecular profiling of tumor specimens. Nature Medicine, 1998, 4, 844-847.	15.2	3,661
353	Molecular cytogenetic mapping of 24 CEPH YACs and 24 gene-specific large insert probes to chromosome 17. Cytogenetic and Genome Research, 1998, 82, 189-191.	0.6	11
354	Positional cloning of ZNF217 and NABC1: Genes amplified at 20q13.2 and overexpressed in breast carcinoma. Proceedings of the National Academy of Sciences of the United States of America, 1998, 95, 8703-8708.	3.3	271
355	Low proportion of BRCA1 and BRCA2 mutations in Finnish breast cancer families: evidence for additional susceptibility genes. Human Molecular Genetics, 1997, 6, 2309-2315.	1.4	128
356	Molecular genetics of human prostate cancer. Current Opinion in Urology, 1997, 7, 259-262.	0.9	0
357	AIB1, a Steroid Receptor Coactivator Amplified in Breast and Ovarian Cancer. Science, 1997, 277, 965-968.	6.0	1,514
358	Androgen Receptor Gene Amplification in a Recurrent Prostate Cancer after Monotherapy with the Nonsteroidal Potent Antiandrogen Casodex (Bicalutamide) with a Subsequent Favorable Response to Maximal Androgen Blockade. European Urology, 1997, 31, 216-219.	0.9	64
359	Linking chromosomal clues. Nature Genetics, 1997, 15, 5-6.	9.4	4
360	Genetic changes associated with the acquisition of androgen-independent growth, tumorigenicity and metastatic potential in a prostate cancer model. British Journal of Cancer, 1997, 75, 190-195.	2.9	60

#	Article	IF	Citations
361	Genome screening by comparative genomic hybridization. Trends in Genetics, 1997, 13, 405-409.	2.9	272
362	Frequent loss of the 11q14-24 region in chronic lymphocytic leukemia: A study by comparative genomic hybridization. , 1997, 19, 286-290.		53
363	Increased copy number at 17q22-q24 by CGH in breast cancer is due to high-level amplification of two separate regions. , 1997, 20, 372-376.		74
364	Comparative genomic hybridization reveals frequent gains of 20q, 8q, 11q, 12p, and 17q, and losses of 18q, 9p, and 15q in pancreatic cancer. Genes Chromosomes and Cancer, 1997, 20, 383-391.	1.5	106
365	Quality control of CGH: Impact of metaphase chromosomes and the dynamic range of hybridization. Cytometry, 1997, 28, 198-205.	1.8	66
366	Major Susceptibility Locus for Prostate Cancer on Chromosome 1 Suggested by a Genome-Wide Search. Science, 1996, 274, 1371-1374.	6.0	717
367	Gains and losses of DNA sequences in malignant mesothelioma by comparative genomic hybridization. Cancer Genetics and Cytogenetics, 1996, 89, 7-13.	1.0	45
368	Comparative genomic hybridization gaining in popularity. Trends in Genetics, 1996, 12, 237-238.	2.9	5
369	Fiber-FISH: experiences and a refined protocol. Genetic Analysis, Techniques and Applications, 1996, 12, 179-184.	1.5	32
370	Low biological aggressiveness of screen-detected lung cancers may indicate over-diagnosis. , 1996, 66, 6-10.		9
371	Evaluation of camera requirements for comparative genomic hybridization. , 1996, 25, 394-398.		9
372	c-erbB-2 in astrocytomas: infrequent overexpression by immunohistochemistry and absence of gene amplification by fluorescence in situ hybridization. British Journal of Cancer, 1996, 73, 620-623.	2.9	24
373	Genetic Basis and Clonal Evolution of Human Prostate Cancer. Advances in Cancer Research, 1996, 68, 225-255.	1.9	55
374	Novel Human Vascular Endothelial Growth Factor Genes VEGF-B and VEGF-C Localize to Chromosomes 11q13 and 4q34, Respectively. Circulation, 1996, 93, 1079-1082.	1.6	88
375	Androgen receptor gene amplification: A novel molecular mechanism for endocrine therapy resistance in human prostate cancer. Scandinavian Journal of Clinical and Laboratory Investigation, 1996, 56, 57-63.	0.6	17
376	Molecular Cytogenetics of Solid Tumor Progression. , 1996, , 68-78.		2
377	The human gene for xanthine dehydrogenase (XDH) is localized on chromosome band 2p22. Cytogenetic and Genome Research, 1995, 68, 61-63.	0.6	19
378	Identification of gains and losses of DNA sequences in primary bladder cancer by comparative genomic hybridization. Genes Chromosomes and Cancer, 1995, 12, 213-219.	1.5	198

#	Article	IF	Citations
379	Hardware and software requirements for quantitative analysis of comparative genomic hybridization. Cytometry, 1995, 19, 4-9.	1.8	86
380	Computer image analysis of comparative genomic hybridization. Cytometry, 1995, 19, 10-26.	1.8	250
381	In vivo amplification of the androgen receptor gene and progression of human prostate cancer. Nature Genetics, 1995, 9, 401-406.	9.4	1,316
382	Mechanically stretched chromosomes as targets for high-resolution FISH mapping.. Genome Research, 1995, 5, 13-20.	2.4	33
383	A physical map of chromosome 20 established using fluorescence in situ hybridization and digital image analysis. Genomics, 1995, 26, 134-137.	1.3	50
384	Visual Mapping by Fiber-FISH. Genomics, 1995, 30, 31-36.	1.3	80
385	ElevatederbB-2 oncoprotein levels in preoperative and follow-up serum samples define an aggressive disease course in patients with breast cancer. Cancer, 1994, 73, 652-658.	2.0	98
386	Optimizing comparative genomic hybridization for analysis of DNA sequence copy number changes in solid tumors. Genes Chromosomes and Cancer, 1994, 10, 231-243.	1.5	1,215
387	Improved technique for analysis of formalin-fixed, paraffin-embedded tumors by fluorescence in situ hybridization. Cytometry, 1994, 16, 93-99.	1.8	116
388	Automated peak detection and cell cycle analysis of flow cytometric DNA histograms. Cytometry, 1994, 16, 250-255.	1.8	33
389	Physical Mapping of Chromosome 17 Cosmids by Fluorescence in Situ Hybridization and Digital Image Analysis. Genomics, 1994, 20, 125-128.	1.3	35
390	Molecular Cytogenetics of Human Breast Cancer. Cold Spring Harbor Symposia on Quantitative Biology, 1994, 59, 645-652.	2.0	23
391	Detection and mapping of amplified DNA sequences in breast cancer by comparative genomic hybridization.. Proceedings of the National Academy of Sciences of the United States of America, 1994, 91, 2156-2160.	3.3	661
392	Consensus review of the clinical utility of dna content cytometry in prostate cancer. Cytometry, 1993, 14, 497-500.	1.8	120
393	Extrachromosomal gene amplification in acute myeloid leukemia; Characterization by metaphase analysis, comparative genomic hybridization, and semi-quantitative PCR. Genes Chromosomes and Cancer, 1993, 8, 185-189.	1.5	44
394	Prognostic value of cells with more than 5c DNA content in node-negative breast cancer as determined by image cytometry from tissue sections. Human Pathology, 1993, 24, 1348-1353.	1.1	10
395	Cathepsin D expression detected by immunohistochemistry has independent prognostic value in axillary node-negative breast cancer.. Journal of Clinical Oncology, 1993, 11, 36-43.	0.8	110
396	Association of Overexpression of Tumor Suppressor Protien p53 With Rapid Cell Proliferation and Poor Prognosis in Node-Negative Breast Cancer Patients. Journal of the National Cancer Institute, 1992, 84, 1109-1114.	3.0	337

#	Article	IF	Citations
397	Small Subgroup of Aggressive, Highly Proliferative Prostatic Carcinomas Defined by p53 Accumulation. Journal of the National Cancer Institute, 1992, 84, 883-887.	3.0	299
398	ERBB2 amplification in breast cancer analyzed by fluorescence in situ hybridization.. Proceedings of the National Academy of Sciences of the United States of America, 1992, 89, 5321-5325.	3.3	493
399	Detection of retinoblastoma gene copy number in metaphase chromosomes and interphase nuclei by fluorescence in situ hybridization. Cytogenetic and Genome Research, 1992, 60, 190-193.	0.6	43
400	Comparative genomic hybridization for molecular cytogenetic analysis of solid tumors. Science, 1992, 258, 818-821.	6.0	3,065
401	Molecular cytogenetics: Diagnosis and prognostic assessment. Current Opinion in Biotechnology, 1992, 3, 623-631.	3.3	25
402	Flow cytometric analysis of DNA ploidy and S-phase fraction from prostatic carcinomas: implications for prognosis and response to endocrine therapy. British Journal of Cancer, 1991, 64, 578-582.	2.9	49
403	Cigarette Smoking Alters Sympathoadrenal Regulation by Decreasing the Density of Î²2-Adrenoceptors. A Study of Monitored Smoking Cessation. Journal of Cardiovascular Pharmacology, 1991, 17, 923-928.	0.8	44
404	Association of C-erbB-2 protein over-expression with high rate of cell proliferation, increased risk of visceral metastasis and poor long-term survival in breast cancer. International Journal of Cancer, 1991, 49, 650-655.	2.3	352
405	Improved prognostic impact of S-phase values from paraffin-embedded breast and prostate carcinomas after correcting for nuclear slicing. Cytometry, 1991, 12, 413-421.	1.8	68
406	Primary undifferentiated small cell carcinoma of the esophagus: Clinicopathological and flow cytometric evaluation of eight cases. Journal of Surgical Oncology, 1991, 46, 174-177.	0.8	45
407	Flow Cytometric Analysis of Tumour dna Profile Related to Response to Radiotherapy and Survival in Inoperable Lung Cancer. Acta OncolÃ³gica, 1990, 29, 983-988.	0.8	14
408	Prognostic factors in recurrent breast cancer: relationships to site of recurrence, disease-free interval, female sex steroid receptors, ploidy and histological malignancy grading. British Journal of Cancer, 1990, 62, 142-146.	2.9	81
409	Inter-laboratory comparison of DNA flow cytometric results from paraffin-embedded breast carcinomas. Breast Cancer Research and Treatment, 1990, 17, 59-61.	1.1	21
410	Steroid receptors and Ki-67 reactivity in ovarian cancer and in normal ovary: Correlation with dna flow cytometry, biochemical receptor assay, and patient survival. Journal of Pathology, 1990, 162, 295-301.	2.1	73
411	Immunoelectron-microscopic localization of a proliferation-associated antigen Ki-67 in MCF-7 cells. The Histochemical Journal, 1990, 22, 498-506.	0.6	34
412	Chapter I. Biology and natural history of breast cancer. International Journal of Cancer, 1990, 46, 5-21.	2.3	51
413	Evaluation of cell proliferation in breast carcinoma. Comparison of Ki-67 immunohistochemical study, DNA flow cytometric analysis, and mitotic count. Cancer, 1990, 65, 1180-1184.	2.0	169
414	Immunohistochemical determination of estrogen and progesterone receptors in human breast carcinoma. Correlation with histopathology and dna flow cytometry. Cancer, 1990, 63, 1761-1767.	2.0	76

#	Article	IF	Citations
415	Analysis of DNA synthesis in herpes simplex virus infected cells by dual parameter flow cytometry. Archives of Virology, 1989, 107, 215-223.	0.9	5
416	Different opinions on classification of DNA histograms produced from paraffin-embedded tissue. Cytometry, 1989, 10, 711-717.	1.8	77
417	Flow cytometric DNA analysis of 199 histologically favourable or unfavourable non-Hodgkin lymphomas. Journal of Pathology, 1989, 157, 27-36.	2.1	50
418	Serum CA 125 in acute pelvic inflammatory disease. BJOG: an International Journal of Obstetrics and Gynaecology, 1989, 96, 574-579.	1.1	25
419	Primary invasive and in situ vaginal carcinoma. Flow cytometric analysis of DNA aneuploidy and cell proliferation from archival paraffin-embedded tissue. European Journal of Obstetrics, Gynecology and Reproductive Biology, 1989, 32, 247-251.	0.5	9
420	Suppression of autologous mixed leukocyte reaction in type 1 diabetes mellitus by in vivo-activated T lymphocytes. Clinical Immunology and Immunopathology, 1989, 52, 406-413.	2.1	6
421	Prognostic Assessment in Stage I Ovarian Cancer Using a Discriminant Analysis with Clinicopathological and DNA Flow Cytometric Data. Gynecologic and Obstetric Investigation, 1989, 27, 213-216.	0.7	12
422	Prognostic significance of dna index, multiploidy, and S-phase fraction in ovarian cancer. Cancer, 1988, 61, 334-339.	2.0	197
423	Improving the prognostic value of DNA flow cytometry in breast cancer by combining DNA index and S-phase fraction: A proposed classification of DNA histograms in breast cancer. Cancer, 1988, 62, 2183-2190.	2.0	240
424	Elevated serum hmfg antigen levels in breast and ovarian cancer patients measured with a sandwich elisa. International Journal of Cancer, 1988, 41, 28-33.	2.3	8
425	DNA flow cytometric analysis indicates that many breast cancers detected in the first round of mammographic screening have a low malignant potential. International Journal of Cancer, 1988, 42, 697-702.	2.3	21
426	Comparison of fresh and paraffin-embedded tissue as starting material for DNA flow cytometry and evaluation of intratumor heterogeneity. Cytometry, 1988, 9, 164-169.	1.8	228
427	Serum CA 15-3 assay in the diagnosis and follow-up of breast cancer. British Journal of Cancer, 1988, 58, 213-215.	2.9	64
428	Lipoprotein uptake in primary cell cultures of rabbit atherosclerotic lesions. Atherosclerosis, 1988, 69, 257-268.	0.4	35
429	DNA Ploidy Level and Cell Cycle Distribution in Ovarian Cancer. International Journal of Gynecological Pathology, 1988, 7, 1-11.	0.9	24
430	Correlation between Serum Tumor Marker Levels and Tumor Proliferation in Small Cell Lung Cancer. Tumor Biology, 1988, 9, 287-292.	0.8	10
431	Nuclear DNA content of non-endemic Burkitt's lymphoma.. Journal of Clinical Pathology, 1987, 40, 1201-1205.	1.0	13
432	Tumour DNA ploidy as an independent prognostic factor in breast cancer. British Journal of Cancer, 1987, 56, 637-642.	2.9	163

#	Article	IF	Citations
433	Aneuploid DNA content and high S-phase fraction of tumour cells are related to poor prognosis in patients with primary breast cancer. European Journal of Cancer & Clinical Oncology, 1987, 23, 277-282.	0.9	134
434	Herpes virus specified early proteins induce cellular DNA synthesis in virus infected cervical cancer cells. European Journal of Cancer & Clinical Oncology, 1987, 23, 1771.	0.9	0
435	Nuclear DNA content characteristics of 129 high grade malignancy non-Hodgkin lymphomas. European Journal of Cancer & Clinical Oncology, 1987, 23, 1775.	0.9	0
436	Prognostic impact of DNA-ploidy and S-phase fraction. European Journal of Cancer & Clinical Oncology, 1987, 23, 1765.	0.9	0
437	Growth properties and composition of cytoskeletal and cytocontractile proteins in aortic cells isolated and cultured from normal and atherosclerotic rabbits. Atherosclerosis, 1984, 52, 13-26.	0.4	18
438	Monensin Induced Oxidative Stress Reduces Prostate Cancer Cell Migration and Cancer Stem Cell Population. , 0, , .		2